WHO disqualifies three combination vaccines of Panacea

Image
BS Reporter New Delhi
Last Updated : Jan 20 2013 | 11:53 PM IST

The World Health Organization (WHO) has removed three combination vaccines of Panacea Biotech from its pre-qualification list.

It took the step after it found deficiencies in the quality management system followed in Panacea’s vaccine manufacturing facility in Punjab.

Shipments of these vaccines – combinations of diphtheria, pertussis, tetanus, Hepatitis B and Hib B vaccines – has been asked to be put on hold until a final decision on the acceptability for United Nations supply has been made by a WHO-convened ad hoc committee. This committee, once constituted, will review the present findings of the audit team. Panacea’s vaccine buyers — UNICEF and the Pan American Health Organization — supply such pre-qualified vaccines to the developing countries.

The company did not give an estimate of the revenue loss expected from the delay in supplies. Panacea’s Easyfive (DTwP-Hep B-Hib), Ecovac4 (DTwP-Hep B), and EnivacHB (Hepatitis B) are the vaccine brands that are under the WHO scanner.

The WHO site audit took place from June 27 - July 1.

In a similar situation a year ago, WHO had suspended pre-qualification granted to a pentavalent vaccine manufactured by Shanta Biotechnics. Despite corrective measures, the company is yet to be qualified for the supplies to international markets.

Panacea’s main revenue earner — oral polio vaccine (OPV) — will continue to be accepted by the WHO. The WHO committee has recommends the continued supply of the OPV vaccines supplied by the company, given that the formulation and filling of the OPV vaccines are carried out at a New Delhi site, where there is no evidence available to WHO of inadequate quality assurance.

An audit by a WHO team of the New Delhi site is scheduled for the coming weeks.

Since there is no evidence of quality or safety defects, batches of these vaccines already distributed to countries will not be recalled and will continue to be used.

In a statement, Panacea said the company has already initiated corrective measures and area confident of completing the process soon.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 19 2011 | 12:36 AM IST

Next Story